As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugmaker—and at least one set of analysts—isn’t sweating what appears to be a slower-than-expected liftoff compared with Novo Nordisk’s rival Wegovy pill.
Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos faces new competition.
While Merck's PAH treatment Winrevair continued its upward trajectory, another of its growth products, COPD medicine Ohtuvayre, took a step back in the first quarter.
Amarox, the U.K. unit of India’s Hetero Group, issued a voluntary recall of one batch of sertraline tablets in Britain after a patient found two different antidepressants packaged together.
Rising Stars: A strategic marketing lead at CDMO Axplora, Arsalan Khan is also a chemical and pharmaceutical engineer, a published author and an avid tennis player.
The FDA has reprimanded Bayer for the “attention-grabbing visuals” and “frequent scene changes” in ads for the company’s prostate cancer drug Nubeqa.
Researchers have identified a new potential weapon against Alzheimer’s: blocking a protein called PTP1B. In mice, this approach boosted memory and helped brain immune cells clear harmful plaque buildup. Since PTP1B is also linked to diabetes and obesity—both risk factors for Alzheimer’s—it could offer a broader treatment strategy.
Merck is making its pitch that high levels of so-called “bad cholesterol” can increase the risk of heart attack or stroke with its new “Playing with Heart” project.
A major review of 217 trials shows that aerobic exercise is the most effective option for managing knee osteoarthritis. Activities like walking, cycling, and swimming outperformed other exercise types in reducing pain and improving movement. While alternatives like strength training and mind-body exercises help, they are best used alongside aerobic workouts. The findings also confirm that exercise
Avalyn Pharma has overshot its expectations with a $300 million IPO that the biotech will use to fund late-stage studies of its inhaled versions of approved respiratory drugs.
The European Medicines Agency (EMA) has launched an advisory group designed to help boost “vaccine confidence” amid growing hesitancy in the region.
Scientists have finally cracked one of the biggest mysteries in the senses: how smell is organized. By mapping millions of neurons in mice, researchers discovered that smell receptors in the nose aren’t random at all—they’re arranged in neat, overlapping stripes based on receptor type, forming a hidden structure scientists never knew existed. Even more striking, this layout mirrors how smell infor
The body’s “killer” T cells don’t just attack—they strike with astonishing precision, forming a tiny, highly organized contact zone that lets them destroy dangerous cells without harming their neighbors. Now, scientists have captured this process in unprecedented detail, revealing a hidden world of molecular choreography.
The appeal is the latest twist in the closely watched lawsuit filed by the American Association of Pediatrics.
At Wednesday's argument, the justices did not appear to question whether skinny labeling is valid.
Novartis will construct an active pharmaceutical ingredient (API) facility in Morrisville, North Carolina, the company said Thursday. The 56,200 square-foot plant will manufacture compounds for solid-dose tablets, capsules and RNA therapeutics.
In this edition of AI Prognosis, Brittany Trang argues that the tide may be turning when it comes to how the health care industry talks about AI.
FDA sampled 312 major infant formula brands and found low or undetectable levels of pesticide residue, PFAS, heavy metals and phthalates.
As AstraZeneca braces for the impact of the U.S. “most favored nation” drug pricing policy, CEO Pascal Soriot suggests that a “very conservative” way to model the fallout would be removing the eight reference markets from future product forecasts.
While Teva Pharmaceutical’s multiyear growth streak under CEO Richard Francis showed signs of leveling off, the company still topped Wall Street estimates in 2026’s first quarter, buoyed by the impressive performance of branded drugs like Austedo, Uzedy and Ajovy.